Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
暂无分享,去创建一个
P. Sonneveld | A. Dinmohamed | M. Minnema | M. Levin | A. Broijl | E. van der Spek | P. Ypma | S. Zweegman | N. V. D. van de Donk | E. Posthuma | M. Brink | E. D. de Waal | K. Groen
[1] A. Chanan-Khan,et al. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. , 2020, Clinical lymphoma, myeloma & leukemia.
[2] M. Boccadoro,et al. Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients , 2020, Cancers.
[3] M. Drayson,et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial , 2019, The Lancet. Oncology.
[4] A. Rambaldi,et al. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis , 2018, American journal of hematology.
[5] M. Boccadoro,et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. , 2018, Critical reviews in oncology/hematology.
[6] L. Trippa,et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma , 2018, British journal of haematology.
[7] Shankar Srinivasan,et al. Recognition of early mortality in multiple myeloma by a prediction matrix , 2017, American journal of hematology.
[8] J. Cheong,et al. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen , 2016, BMC Cancer.
[9] C. Teng,et al. Early mortality in multiple myeloma: Experiences from a single institution , 2016, Hematology.
[10] U. Mellqvist,et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.
[11] H. Goldschmidt,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[12] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[13] P. Sonneveld,et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials , 2013, Haematologica.
[14] G. Morgan,et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.